报价延迟最少15分钟:2026/04/17 06:21 EDT
盘前时段
|
||||
|
10.57 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.61/--
|
|
企业价值
1.49B
|
| 资产负债 |
|
每股账面净值
4.21
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
48.27M
|
|
每股收益
0.69
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States. |
